Aptose Biosciences Inc. (TSE:APS – Get Free Report) (NASDAQ:APTO) hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as C$0.20 and last traded at C$0.21, with a volume of 85632 shares changing hands. The stock had previously closed at C$0.26.
Aptose Biosciences Stock Performance
The company has a market capitalization of C$10.12 million, a P/E ratio of -0.05 and a beta of 1.36. The stock has a fifty day simple moving average of C$0.30 and a 200-day simple moving average of C$0.43. The company has a quick ratio of 5.41, a current ratio of 1.05 and a debt-to-equity ratio of -117.37.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Read More
- Five stocks we like better than Aptose Biosciences
- How to Short a Stock in 5 Easy Steps
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
- The Basics of Support and Resistance
- MercadoLibre: High-Growth EM Stock With 100% Upside Potential
- Are Penny Stocks a Good Fit for Your Portfolio?
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
